Sequenom Patent Invalidation May Have Ramifications for NIPT Field, Entire MDx Industry | GenomeWeb

NEW YORK (GenomeWeb) – The invalidation of a broad patent held by Sequenom in the noninvasive prenatal testing field may impact not only the litigious NIPT field but also the molecular diagnostics industry as a whole, according to patent law experts.

Last week, the US Court of Appeals for the Federal Circuit upheld a previous ruling by the US District Court for the Northern District of California that the claims of Sequenom's US Patent No. 6,258,540 are not patent eligible.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.